Aflibercept；阿帕西普
分子式：C4318H6788N1164O1304S32分子量：96.89KD
简介： Aflibercept is a recombinant fusion protein and acts as a VEGF inhibitor. Aflibercept is used for the treatment of wet macular degeneration and metastatic colorectal cancer.
产品形式：蛋白原液 。每种装于冻存管中，单抗质量为标示数量1MG或者5MG，体积根据其浓度不同略有不同。
质量标准：
Non-reduced CE-SDS:………………………………………….>90%;
SEC-HPLC:………………………………………………………….>95%;
Bacterial Endotoxins Test：…………………………………. .<10EU/ml
Residual Proteins of Host Cell: ……………………………. <100 ng/mg
Exogenous residual DNA: …………………………………. . <100pg/mg
Residual Protein A: ……………………………………………. .<100 ng/mg
Biological Activity:………………………………………….……. .80% to 125% of standard
储存条件：-70 ± 15℃for long-term storage, 2-8℃for short-term storage, away from light.
运输条件：干冰运输
使用建议：
提供的产品为蛋白原液形式。每种装于冻存管中，单抗质量为标示数量1MG或者5MG，体积根据其浓度不同略有不同。
使用前可以根据自己实验需求进行稀释，溶剂建议用去离子无菌水(货号MA0028，去离子无菌水(细胞培养用水))或者PBS（货号MA0015 PBS(1X),细胞培养级）。
不建议使用含有防腐成分的稀释液进行稀释，会增加细胞或者动物毒性。
稀释前，计算加入多少体积溶剂，请参考购买批次质检单上蛋白浓度，或者询问我司，
举例，质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml
对应5MG包装的蛋白原液体积为5mg（质量）/50mg/ml(浓度)=0.1ML，
实验需求蛋白浓度为10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入0.4ML,即400ul PBS或者无菌去离子水即可。
若给药量为固定质量值，比如单次给药0.5MG，对应蛋白原液给药体积为10ul，建议稀释后，提高给药体积降低误差，因为注射器或者移液器吸头残留会影响实验效果。
稀释后的蛋白溶液，可于2-8度冷藏避光保存不超过2周，不建议长期储存。
避免反复冻融，每次冻融蛋白活性会降低约5%左右。
生物活性（仅来自于公开文献，不保证其有效性）
|
描述
|
Aflibercept is a recombinant fusion protein and acts as a VEGF inhibitor. Aflibercept is used for the treatment of wet macular degeneration and metastatic colorectal cancer. |
|
靶点 |
VEGFR |
|
Description |
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrate and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain. Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). |
相关产品推荐(更多相关靶点抑制剂请详询官网或客服)
|
产品编号
|
品名. |
Target |
|
MB2784 |
Adalimumab |
TNF-α |
|
MB2786 |
Alemtuzumab |
CD52 |
|
MB2787 |
Alirocumab |
PCSK9 |
|
MB2789 |
Avelumab |
PDL-1 |
|
MB2790 |
Atezolizumab |
PDL-1 |
|
MB2791 |
Bevacizumab |
VEGF |
|
MB2792 |
Cetuximab |
EGFR |
|
MB2803 |
Daratumumab |
CD38 |
|
MB2794 |
Denosumab |
RANK Ligand |
|
MB2023 |
Eculizumab |
补体蛋白(C5) |
|
MB2795 |
Etanercept |
TNF |
|
MB2797 |
Evolocumab |
PCSK9 |
|
MB2773 |
Infliximab |
TNF-α |
|
MB2769 |
Ipilimumab |
CTLA-4 |
|
MB2772 |
Matuzumab |
EGFR |
|
MB2766 |
Mepolizumab |
IL-5 |
|
MB2767 |
Nivolumab |
PD-1 |
|
MB2774 |
Obinutuzumab |
CD20 |
|
MB2776 |
Ofatumumab |
CD20 |
|
MB2777 |
Omalizumab |
IgE |
|
MB2781 |
Panitumumab |
EGFR |
|
MB2761 |
Pembrolizumab |
PD-1 |
|
MB2762 |
Pertuzumab |
HER2 |
|
MB2763 |
Ranibizumab |
VEGFR |
|
MB2938 |
Ramucirumab |
VEGFR |
|
MB2749 |
Rituximab |
CD20 |
|
MB2757 |
Secukinumab |
IL-17 |
|
MB2751 |
Tocilizumab/Atlizumab |
IL-6 receptor |
|
MB2753 |
Trastuzumab |
ErbB2 |
|
MB2758 |
Ustekinumab |
IL-12 |
用途及描述：仅供科研，严禁用于人体(For R&D Only)
备注：所有报价均已含国内快递费及发票费用。库存情况可能有所变动，请与我们销售人员确认为准，价格情况请直接联系我们销售人员。
我司所售出产品仅供于科研研究用途（非临床科研研究），每次销售产品行为都适用于我司网上所列明的。
CAS 号：845771-78-0
英文名字：阿帕西普